Based on the findings that USP12 downregulation resulted in increased TAM recruitment, enhanced PD-L1 expression and impaired T cell activation in syngeneic mouse tumours, we, therefore, extended our study to observe whether USP12 in cancer cells could influence their response to PD-1 immune checkpoint blockade. This evidence concerns the gene USP12 and neoplasm.